CTTHWGFTLC, CYCLIC TFA

Cat. No.: HY-P1789A

Molecular Formula: $C_{54}H_{72}F_3N_{13}O_{16}S_2$

Molecular Weight: 1280.35

Sequence: Cys-Thr-Thr-His-Trp-Gly-Phe-Thr-Leu-Cys (Disulfide Bridge: Cys1-Cys10)

Sequence Shortening: CTTHWGFTLC (Disulfide Bridge: Cys1-Cys10)

CTTHWGFTLC (Disulfide Bridge: Cys1-Cys10) (TFA salt)

Target: MMP

Pathway: Metabolic Enzyme/Protease

Storage: Sealed storage, away from moisture and light, under nitrogen

Powder -80°C 2 years

-20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 50 mg/mL (39.05 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	0.7810 mL	3.9052 mL	7.8104 mL
	5 mM	0.1562 mL	0.7810 mL	1.5621 mL
	10 mM	0.0781 mL	0.3905 mL	0.7810 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC_{50} value for MMP-9 is ~8 μM[1].

IC_{50} & Target	MMP-2	MMP-9

In Vitro CTTHWGFTLC, CYCLIC TFA inhibits endothelial and tumor cell migration in vitro[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo CTTHWGFTLC, CYCLIC TFA inhibits tumor progression in vivo, in mouse models[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Medina OP, et al. Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro. Cancer Res. 2001 May 15;61(10):3978-85.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA